Hemostatic and fibrinolytic response to nasal desmopressin in hemodialysis patients

Creative Commons License

Ulusoy Ş., Ovali E., Aydin F., Erem C., Ozdemir F., Kaynar K.

MEDICAL PRINCIPLES AND PRACTICE, vol.13, no.6, pp.340-345, 2004 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 13 Issue: 6
  • Publication Date: 2004
  • Doi Number: 10.1159/000080471
  • Journal Name: MEDICAL PRINCIPLES AND PRACTICE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.340-345
  • Keywords: nasal desmopressin, hemodialysis patients, hemostasis, VONWILLEBRAND-FACTOR, UREMIA, MANAGEMENT, PLATELETS, DIALYSIS, BINDING, DEFECT
  • Karadeniz Technical University Affiliated: Yes

Abstract

Objective: To evaluate the effect of desmopressin ( DDAVP) on hemostatic parameters during dialysis and in the interval between dialysis sessions. Subjects and Methods: Fifteen patients dialyzed twice weekly at least for 1 year and 15 healthy volunteers serving as a control group were enrolled in the study. Bleeding time, platelet count, prothrombin time, activated partial thromboplastin time, tissue plasminogen activator (tPA), plasminogen activator inhibitor (PAI-1), euglobulin clot lysis time, protein C, protein S, fibrinogen, D-dimer, factor V, VII, VIII, IX, X and von Willebrand factor (VWF) values were studied at the beginning, at 2 and 4 h of dialysis with and without administration of DDAVP at a dose level of 2 mug/kg intranasally. Results: After dialysis, bleeding time shortened, PAI-1 and fibrinogen levels were lower, while VWF and D-dimer levels were higher. After DDAVP administration, bleeding time, PAI-1 levels were significantly lower (p < 0.01), while tPA, factor VIII and VWF levels increased significantly (p < 0.001). Conclusion: The findings indicate that DDAVP can be used for patients on dialysis with serious bleeding. Copyright (C) 2004 S. Karger AG, Basel.